CA2202066A1 - Lignees immortalisees de cellules endotheliales cerebrales et leurs applications therapeutiques - Google Patents

Lignees immortalisees de cellules endotheliales cerebrales et leurs applications therapeutiques

Info

Publication number
CA2202066A1
CA2202066A1 CA002202066A CA2202066A CA2202066A1 CA 2202066 A1 CA2202066 A1 CA 2202066A1 CA 002202066 A CA002202066 A CA 002202066A CA 2202066 A CA2202066 A CA 2202066A CA 2202066 A1 CA2202066 A1 CA 2202066A1
Authority
CA
Canada
Prior art keywords
cells
vector
endothelial
gene
endothelial cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002202066A
Other languages
English (en)
French (fr)
Inventor
Nathalie Chaverot
Pierre-Olivier Couraud
John Laterra
Jerome Quinonero
Francoise Roux
Arthur Donny Strosberg
Jean-Leon Tchelingerian
Lionel Vignais
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurotech Pharmaceuticals Inc
Original Assignee
ASSOCIATION POUR LE DEVELOPPEMENT DE L'IMMUNOLOGIE MOLECULAIRE-ADIM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ASSOCIATION POUR LE DEVELOPPEMENT DE L'IMMUNOLOGIE MOLECULAIRE-ADIM filed Critical ASSOCIATION POUR LE DEVELOPPEMENT DE L'IMMUNOLOGIE MOLECULAIRE-ADIM
Publication of CA2202066A1 publication Critical patent/CA2202066A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002202066A 1994-10-10 1995-10-09 Lignees immortalisees de cellules endotheliales cerebrales et leurs applications therapeutiques Abandoned CA2202066A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR94/12078 1994-10-10
FR9412078A FR2726005B1 (fr) 1994-10-10 1994-10-10 Lignees immortalisees de cellules endotheliales cerebrales et leurs applications au traitement de differents troubles ou maladies primaires et secondaires neurologiques ou psychiatriques

Publications (1)

Publication Number Publication Date
CA2202066A1 true CA2202066A1 (fr) 1996-04-18

Family

ID=9467723

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002202066A Abandoned CA2202066A1 (fr) 1994-10-10 1995-10-09 Lignees immortalisees de cellules endotheliales cerebrales et leurs applications therapeutiques

Country Status (7)

Country Link
EP (1) EP0787197A1 (xx)
JP (1) JPH10507074A (xx)
AU (1) AU715289B2 (xx)
CA (1) CA2202066A1 (xx)
FR (1) FR2726005B1 (xx)
NZ (1) NZ293994A (xx)
WO (1) WO1996011278A1 (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999035255A2 (en) * 1998-01-12 1999-07-15 Betagene, Inc. Compositions and methods for regulated secretion from neuroendocrine cell lines
US6093553A (en) * 1998-11-25 2000-07-25 Boehringer Ingelheim Pharmaceuticals, Inc. Immortalized brain endothelial cells
WO2000032751A2 (en) * 1998-11-30 2000-06-08 Neurotech (S.A.) Mammalian non-neuronal cells that are modified to store and release a neurotransmitter
FR2787464B1 (fr) * 1998-12-21 2003-01-10 Neurotech Compositions pharmaceutiques comprenant des cellules endotheliales immortalisees pour la detection et/ou le traitement des sources angiogeniques et tout particulierement des cancers
FR2787463B1 (fr) * 1998-12-21 2001-03-30 Neurotech Preparation de cellules de mammifere eventuellement transfectees avec un gene codant pour une substance active et les compositions les contenant
KR100674140B1 (ko) * 1999-03-23 2007-01-26 다카라 바이오 가부시키가이샤 유전자 치료제
WO2001083716A2 (en) * 2000-05-03 2001-11-08 Neurotech S.A. Immortalized lines of endothelial brain cells and therapeutic application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3851153T2 (de) * 1987-12-11 1995-01-05 Hughes Howard Med Inst Genetische modifizierung von endothelialen zellen.
ATE163046T1 (de) * 1990-10-31 1998-02-15 Somatix Therapy Corp Genetische veränderung von endothelzellen
WO1992017569A1 (en) * 1991-04-04 1992-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immortalization of endothelial cells
FR2681609B1 (fr) * 1991-09-24 1994-12-30 Centre Nat Rech Scient Lignees de cellules endotheliales cerebrales immortalisees, leur procede de preparation et leurs applications en tant que modele d'etude de la physiopathologie cerebrale.
US5336615A (en) * 1992-01-06 1994-08-09 Yale University Genetically engineered endothelial cells exhibiting enhanced migration and plasminogen activator activity
WO1993013807A1 (en) * 1992-01-10 1993-07-22 Georgetown University A method of administering genetically engineered endothelial cells to sites of angiogenesis for effecting genetic therapy
GB9222931D0 (en) * 1992-11-02 1992-12-16 Sandoz Ltd Organic compounds

Also Published As

Publication number Publication date
JPH10507074A (ja) 1998-07-14
WO1996011278A1 (fr) 1996-04-18
FR2726005B1 (fr) 1997-01-03
FR2726005A1 (fr) 1996-04-26
AU715289B2 (en) 2000-01-20
EP0787197A1 (fr) 1997-08-06
AU3657595A (en) 1996-05-02
NZ293994A (en) 1999-02-25

Similar Documents

Publication Publication Date Title
US20230149469A1 (en) Wound healing and tissue engineering
Liu et al. Intraspinal delivery of neurotrophin-3 using neural stem cells genetically modified by recombinant retrovirus
Chino et al. Bone marrow cell transfer into fetal circulation can ameliorate genetic skin diseases by providing fibroblasts to the skin and inducing immune tolerance
US20050202075A1 (en) Delivery of genes encoding short hairpin RNA using receptor-specific nanocontainers
JP2005517717A (ja) 希突起膠細胞前駆細胞を用いた先天性髄鞘発育不全の前脳の有髄化
Mercapide et al. Primary gene‐engineered neural stem/progenitor cells demonstrate tumor‐selective migration and antitumor effects in glioma
US20180051249A1 (en) Methods for making neural stem cells and uses thereof
KR19980702119A (ko) 인간 췌장 세포계: 개발 및 용도
JP2008303215A (ja) ベクターシステム
WO1999000146A1 (en) Development and use of human pancreatic cell lines
Arnhold et al. Neural precursor cells as carriers for a gene therapeutical approach in tumor therapy
US5667777A (en) Delivery of gene products via mesangial cells
CN1325637C (zh) 室管膜神经干细胞及其分离方法
CA2202066A1 (fr) Lignees immortalisees de cellules endotheliales cerebrales et leurs applications therapeutiques
Ojeifo et al. Angiogenesis-directed implantation of genetically modified endothelial cells in mice
EP0781344B1 (fr) Nouvel implant et nouveau vecteur pour le traitement des maladies acquises
JP2004533234A (ja) カプセル化細胞インジケータシステム
Kirshner et al. Cell–cell adhesion molecule CEACAM1 is expressed in normal breast and milk and associates with β1 integrin in a 3D model of morphogenesis
JPH10513358A (ja) ヒト膵臓細胞系：発達と用途
DE69732710T2 (de) Mononukleare phagozyten zur verabreichung von therapeutischen arzneimitteln
CA2558436A1 (en) Method of proliferating precursor cells
KR100674140B1 (ko) 유전자 치료제
KR100814066B1 (ko) Ｔｒａｉｌ을 분비하는 인간의 신경줄기세포, 이의제조방법 및 용도
WO2023087548A1 (zh) Cpe在制备促进原位神经发生及治疗衰老相关神经退行性疾病药物中的应用
Shah et al. Genetic modification of adipose-derived stem cells for bone regeneration

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead